Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Patients
2026-000042-29Phase 3
- Sponsor
- Roche
- Start
- Feb 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of emicizumab in hemophilia A (2 arms), sponsored by Roche. Primary endpoint: Annualized bleeding rate (ABR) for treated bleeds.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2026-000042-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-000042-29.